The family-run business features small-batch, kosher ice cream with creative, house-made flavors. Lily's uses high-quality ingredients like 16% butterfat, cane sugar, and offers vegan options. The ...
Eli Lilly and Company announced results from the primary overall survival (OS) analysis of the phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) reduced ...
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...
Serena & Lily and Lilly Pulitzer collaborated on a holiday-themed tablescape for a "Dress the Table" event in Palm Beach. The design combined Serena & Lily's calming style with Lilly Pulitzer's ...
(RTTNews) - Eli Lilly and Company (LLY) on Friday reported that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% compared with endocrine therapy alone in ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the ...
TORONTO, Oct. 17, 2025 /CNW/ - Eli Lilly and Company today announced results from the primary overall survival (OS) analysis of the Phase 3 monarchE trial showing that two years of adjuvant Verzenio ...
Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s Verzenio has proven it can extend patients’ lives in the indication. Verzenio ...
Survive on a frozen island, building and living in a makeshift shelter on a snowy beach. #SurvivalAdventure #SnowCamping #SurvivalShelter Marine Colonel Who Resigned Because Of Trump Says Personnel ...
The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to ...
Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback